The evidence hierarchy
Researchers grade evidence on a ladder from weakest to strongest. Higher rungs are more reliable because they better control for bias and chance:[1]
- Cell / test-tube (in vitro) — a starting point; shows a molecule can do something in isolation.
- Animal studies — useful for hypotheses, but a long way from proving human benefit.
- Case reports & anecdotes — individual stories; cannot separate effect from coincidence.
- Small / observational human studies — suggestive, but prone to confounding.
- Randomized controlled trials (RCTs) — the gold standard for showing a treatment actually works.
- Systematic reviews & meta-analyses — the top rung, pooling all the good trials together.
When someone says "studies show," the first question is always: which rung?
Why “works in mice” rarely means proven
The most common way peptide claims mislead is by presenting animal results as if they were human proof. The reality is that the large majority of compounds that look promising in animals fail when finally tested in people — biology differs, and lab conditions are idealized. That gap is exactly why popular animal-only peptides like BPC-157 and TB-500 remain unproven in humans despite impressive rodent data. Animal evidence is a reason to investigate further, not a reason to believe.
What “FDA-approved” actually means
FDA approval is the strongest practical signal that a peptide works in people, because it requires passing human clinical trials:
- Phase 1 — is it safe, and at what dose?
- Phase 2 — does it show a useful effect?
- Phase 3 — does it beat placebo (or standard care) in a large, randomized trial?
Approval means regulators judged the benefits to outweigh the risks for a specific use. That's why approved peptides like semaglutide sit at the top of the evidence ladder, while "research chemicals" sit near the bottom. See also Are peptides legal?
Red flags in peptide claims
- Testimonials instead of trials. Before-and-after stories are marketing, not evidence.
- "Studies show" with no specific citation — or a citation that turns out to be an animal or cell study.
- Animal results framed as human-proven.
- No completed human trials for a compound sold as effective.
- Cherry-picked single studies that ignore the wider literature.
- The source profits from selling the compound.
How we grade evidence on The Peptide Almanac
We label the evidence tier on every guide — from approved medicines with large trials down to preclinical research chemicals — and we say plainly when evidence is weak or animal-only. Our full method is in the editorial policy. The goal is simple: never let a peptide sound more proven than it actually is.
Frequently asked questions
What is the strongest type of medical evidence?
Systematic reviews and meta-analyses of randomized controlled trials sit at the top, followed by individual RCTs. Cell and animal studies are the weakest rungs — useful for generating hypotheses, but not for proving benefit in people.
Why don't animal studies count as proof?
Most compounds that work in animals fail when tested in humans, because animal biology differs and lab conditions are idealized. Animal results are a starting point for investigation, not proof of human safety or efficacy.
What does FDA-approved tell me about the evidence?
It means the drug passed human clinical trials (phases 1–3) showing its benefits outweigh its risks for a specific use. It's the strongest practical signal that a peptide actually works in people.
How can I spot weak peptide evidence?
Watch for claims based on testimonials or animal studies, 'studies show' without a specific citation, no completed human trials, cherry-picked single studies, and sources that profit from selling the compound.
Further reading
Selected peer-reviewed sources on this topic, labelled by type. A citation is a reference, not an endorsement.
- Wallace SS, Barak G, Truong G, et al. Hierarchy of Evidence Within the Medical Literature. Hosp Pediatr. 2022. Peer-reviewed study
- Daly J, Willis K, Small R, et al. A hierarchy of evidence for assessing qualitative health research. J Clin Epidemiol. 2007. Peer-reviewed study
- Jamshidi S, Pati D. Hierarchy of Evidence: An Appraisal Tool for Weighting the Evidence in Healthcare Design Research Based on Internal Validity. HERD. 2023. Peer-reviewed study